21.2.2025

Ardeypharm and XO Life: brite™ platform enables digital support for Mutaflor®

Mutaflor is the first digital treatment area on the brite™ platform for chronic constipation and bowel inflammation

Munich, Germany, February 21, 2025 - Ardeypharm, a leading provider of microbiological medicines to support gut health, and XO Life, developer of the brite™ platform, announce their collaboration. Ardeypharm is a family-owned company active in the manufacture, distribution and research of a wide range of intestinal therapeutic agents and phytopharmaceuticals. Users who use Mutaflor® as a probiotic medicine to support the intestinal flora now have access to the diverse functions of the brite™ platform from XO Life. After registering for free on the platform and in the special Mutaflor® area of Ardeypharm, users receive further information on the preparation, helpful health tips and can gain insights into the course of therapy and follow it digitally.

Mutaflor® supports the intestinal flora and the immune system

A healthy gut microbiota is crucial for general well-being and immune defence. However, millions of people suffer from various digestive problems, often due to an imbalance in the gut microbiota.¹ The active ingredient in Mutaflor® is the medicinal gut bacteria E. coli strain Nissle 1917, which supports gut health through various mechanisms, including inhibition of pathogens, stimulation of the immune system and promotion of the intestinal barrier function. Mutaflor® is used to support the treatment of chronic intestinal complaints such as ulcerative colitis and irritable bowel syndrome. It is known for its positive effect on the balance of the intestinal microbiota.^2,3

brite™ platform: Digital therapy support for Mutaflor® users

Mutaflor® users can now use the brite™ platform as a helpful supplement to taking the probiotic medicine. Registration is possible via your own Ardeypharm Mutaflor® access on the web or in the app for iOS and Android. The Mutaflor® section on the Meta platform provides scientifically sound information on intestinal health and the medicine. Users can receive tips on how to support their intestinal flora, track their well-being and understand the effect of the probiotic on their individual intestinal health. Based on the data collected, the platform also offers general recommendations to support well-being, which can serve as a guide for conscious therapy design.

XO Life brite™ platform: strengthening user support through digital innovation

By partnering with XO Life, Ardeypharm strengthens its position as a forward-thinking company and enables Mutaflor® users to benefit from the advantages of the brite™ platform. ‘The decision to partner with XO Life reflects Ardeypharm's continuous drive for innovation. With this partnership, we are expanding our offering for Mutaflor® users with a digital therapy support that effectively combines nature-based approaches and advanced technologies,’ says Adam Faßbender, Managing Director Marketing Sales at Ardeypharm.

Dr Friderike Bruchmann, Co-Founder & CEO of XO Life, adds: ‘By partnering with Ardeypharm, we are opening up new ways to integrate innovative digital solutions into microbiological therapy. Our brite™ platform offers Mutaflor® users the opportunity to better understand and actively participate in their therapy.’

About Ardeypharm GmbH

As an owner-managed medium-sized company, Ardeypharm GmbH develops, produces and distributes medicinal products and medical devices across a wide range of applications for the benefit of patients. Based on this responsibility, an important research focus for over 50 years has been the further development of microbiological active ingredients for practical use. Mutaflor is the only product of its kind in Europe to demonstrate the anti-inflammatory efficacy of a probiotic drug for maintaining remission in ulcerative colitis. Other products are also used in the treatment of intestinal transit disorders, e.g. in the treatment of acute diarrhoea (Yomogi 250 mg) or chronic constipation in children (Juniorlax), as well as for reflux complaints (Fluxan).

Ardeypharm produces and distributes a wide range of phytopharmaceuticals in the knowledge that nature also has many natural active ingredients for the benefit of health. The range of phytopharmaceuticals includes Ardeyhepan to support liver function, Passidon for nervous restlessness, Doloteffin for the natural treatment of joint complaints and Ardeybronchol for the treatment of respiratory colds. With the promise to always give the best for the health of their patients, a highly motivated team works daily to expand the range and strengthen innovations. This is supported by a diverse, nationwide training programme for healthcare professionals and patients as well as informative social media campaigns.

Website: https://www.ardeypharm.de

About XO Life

XO Life has created a globally unique meta-platform, the brite™ platform, for digital product and therapy support for patients. Patients are accompanied during their product application or therapy with verified medical and health-related content, record their health and therapy progress, receive personalised insights and medical support from experts and can exchange information with other patients. Manufacturers can licence their own product and therapy areas on the brite™ platform and make them available to their patients with their own branding, content, questions and services. By providing personalised information and continuous support during therapies, manufacturers make an important contribution to the success of therapy, treatment adherence and application safety for patients.

XO Life is one of the great hopes in the healthcare sector and is one of the leading digital health start-ups in Germany and Europe. In March 2023, XO Life was nominated for the Digital Award by the Federal Ministry of Economics and Climate Protection as one of 10 start-ups from various sectors of the economy. XO Life works with global market leaders, German pharmaceutical SMEs and orphan drug manufacturers and now offers the brite™ platform in all European countries and languages.

‍